The headline for today’s post reflects a mix of forward looking optimism with some (hopefully) balanced critical analysis.

The KA-pow! Effect – Created by DALL-E

Gone are the days of what I think of as the old school heavy handed antibody-drug conjugates (ADCs), where they were rather challenging to finesse in terms of the therapeutic window because you couldn’t dose high enough to exert the desired effect before the dreaded dose limiting toxicities whacked everything out of balance.

In the real life game of snakes and ladders, many an investigator would quickly become frustrated with too few little ladders up and long snakes back down trying to find an acceptable sweet spot in the dose schedules for their patients.

In terms of framing the new ADC frontier – these days things are a’changing much more rapidly when we consider the sheer number of novel molecules coming through company pipelines. Of course, not all agents in Phase 1 will succeed when considering there’s a long way to go to the approval line.

In this review we talk about some recent clinical and scientific developments, including two emerging and unexpected biomarkers of interest.

We thought about each update in the context of three key areas:

  • Innovations leading the charge
  • Challenges on the horizon
  • The ADC ecosystem in transition

As always, not all of the early promise in clinical trials will be completely rosy since there are tricky or unexpected hurdles to consider…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by